Rajmonda Fjerza

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

M. Gobbi, G. Gaidano, A. Pancrazzi, 2015, Drug design, development and therapy.

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

S. Verstovsek, P. Guglielmelli, A. Pancrazzi, 2015, Blood.

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

T. Barbui, D. Larson, P. Guglielmelli, 2014, Blood.

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

M. Cazzola, P. Guglielmelli, R. Manfredini, 2014, Blood.

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

M. Cazzola, T. Barbui, G. Cimino, 2014 .